|
1.
|
Yu MC and Yuan JM: Epidemiology of
nasopharyngeal carcinoma. Semin Cancer Biol. 12:421–429. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Qin DX, Hu YH, Yan JH, et al: Analysis of
1379 patients with nasopharyngeal carcinoma treated by radiation.
Cancer. 61:1117–1124. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Pua KC, Khoo AS, Yap YY, et al:
Nasopharyngeal Carcinoma Database. Med J Malaysia. 63(Suppl C):
59–62. 2008.
|
|
4.
|
Lee AW, Poon YF, Foo W, et al:
Retrospective analysis of 5037 patients with nasopharyngeal
carcinoma treated during 1976–1985: overall survival and patterns
of failure. Int J Radiat Oncol Biol Phys. 23:261–270.
1992.PubMed/NCBI
|
|
5.
|
Agulnik M and Epstein JB: Nasopharyngeal
carcinoma: current management, future directions and dental
implications. Oral Oncol. 44:617–627. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Pathmanathan R, Prasad U, Sadler R, Flynn
K and Raab-Traub N: Clonal proliferations of cells infected with
Epstein-Barr virus in preinvasive lesions related to nasopharyngeal
carcinoma. N Engl J Med. 333:693–698. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
8.
|
McDonald SL and Silver A: The opposing
roles of Wnt-5a in cancer. Br J Cancer. 101:209–214. 2009.
View Article : Google Scholar
|
|
9.
|
Ying J, Li H, Yu J, et al: WNT5A exhibits
tumor-suppressive activity through antagonizing the
Wnt/beta-catenin signaling, and is frequently methylated in
colorectal cancer. Clin Cancer Res. 14:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Dejmek J, Dejmek A, Safholm A, Sjolander A
and Andersson T: Wnt-5a protein expression in primary dukes B colon
cancers identifies a subgroup of patients with good prognosis.
Cancer Res. 65:9142–9146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Blanc E, Roux GL, Benard J and Raguenez G:
Low expression of Wnt-5a gene is associated with high-risk
neuroblastoma. Oncogene. 24:1277–1283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Jonsson M, Dejmek J, Bendahl PO and
Andersson T: Loss of Wnt-5a protein is associated with early
relapse in invasive ductal breast carcinomas. Cancer Res.
62:409–416. 2002.PubMed/NCBI
|
|
13.
|
Dejmek J, Leandersson K, Manjer J, et al:
Expression and signaling activity of Wnt-5a/discoidin domain
receptor-1 and Syk plays distinct but decisive roles in breast
cancer patient survival. Clin Cancer Res. 11:520–528.
2005.PubMed/NCBI
|
|
14.
|
Ying J, Li H, Chen YW, Srivastava G, Gao Z
and Tao Q: WNT5A is epigenetically silenced in hematologic
malignancies and inhibits leukemia cell growth as a tumor
suppressor. Blood. 110:4130–4132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Roman-Gomez J, Jimenez-Velasco A, Cordeu
L, et al: WNT5A, a putative tumour suppressor of lymphoid
malignancies, is inactivated by aberrant methylation in acute
lymphoblastic leukaemia. Eur J Cancer. 43:2736–2746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Liang H, Chen Q, Coles AH, et al: Wnt5a
inhibits B cell proliferation and functions as a tumor suppressor
in hematopoietic tissue. Cancer Cell. 4:349–360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Da Forno PD, Pringle JH, Hutchinson P, et
al: WNT5A expression increases during melanoma progression and
correlates with outcome. Clin Cancer Res. 14:5825–5832.
2008.PubMed/NCBI
|
|
18.
|
Fernandez-Cobo M, Zammarchi F, Mandeli J,
Holland JF and Pogo BG: Expression of Wnt5A and Wnt10B in
non-immortalized breast cancer cells. Oncol Rep. 17:903–907.
2007.PubMed/NCBI
|
|
19.
|
Kurayoshi M, Oue N, Yamamoto H, et al:
Expression of Wnt-5a is correlated with aggressiveness of gastric
cancer by stimulating cell migration and invasion. Cancer Res.
66:10439–10448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ripka S, Konig A, Buchholz M, et al: WNT5A
- target of CUTL1 and potent modulator of tumor cell migration and
invasion in pancreatic cancer. Carcinogenesis. 28:1178–1187. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Huang CL, Liu D, Nakano J, et al: Wnt5a
expression is associated with the tumor proliferation and the
stromal vascular endothelial growth factor - an expression in
non-small-cell lung cancer. J Clin Oncol. 23:8765–8773. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wang Q, Williamson M, Bott S, et al:
Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.
Oncogene. 26:6560–6565. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Bose S, Yap LF, Fung M, et al: The ATM
tumour suppressor gene is down-regulated in EBV-associated
nasopharyngeal carcinoma. J Pathol. 217:345–352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Zeng ZY, Zhou YH, Zhang WL, et al: Gene
expression profiling of nasopharyngeal carcinoma reveals the
abnormally regulated Wnt signaling pathway. Hum Pathol. 38:120–133.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Hu C, Wei W, Chen X, et al: A global view
of the oncogenic landscape in nasopharyngeal carcinoma: an
integrated analysis at the genetic and expression levels. PLoS One.
7:e410552012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Moody CA, Scott RS, Amirghahari N, et al:
Modulation of the cell growth regulator mTOR by Epstein-Barr
virus-encoded LMP2A. J Virol. 79:5499–5506. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shah KM, Stewart SE, Wei W, et al: The
EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the
actions of interferon by targeting interferon receptors for
degradation. Oncogene. 28:3903–3914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Allen MD, Young LS and Dawson CW: The
Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote
epithelial cell spreading and motility. J Virol. 79:1789–1802.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Yap LF, Jenei V, Robinson CM, et al:
Upregulation of Eps8 in oral squamous cell carcinoma promotes cell
migration and invasion through integrin-dependent Rac1 activation.
Oncogene. 28:2524–2534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Tulalamba W and Janvilisri T:
Nasopharyngeal carcinoma signaling pathway: an update on molecular
biomarkers. Int J Cell Biol. 2012.5946812012.PubMed/NCBI
|
|
31.
|
Ge X, Yamamoto S, Tsutsumi S, et al:
Interpreting expression profiles of cancers by genome-wide survey
of breadth of expression in normal tissues. Genomics. 86:127–141.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yap YY, Hassan S, Chan M, Choo PK and
Ravichandran M: Epstein-Barr virus DNA detection in the diagnosis
of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg.
136:986–991. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Dawson CW, Port RJ and Young LS: The role
of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the
pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol.
22:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Morrison JA and Raab-Traub N: Roles of the
ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A
in the inhibition of epithelial cell differentiation and activation
of {beta}-catenin signaling. J Virol. 79:2375–2382. 2005.PubMed/NCBI
|
|
35.
|
Morrison JA, Klingelhutz AJ and Raab-Traub
N: Epstein-Barr virus latent membrane protein 2A activates
beta-catenin signaling in epithelial cells. J Virol.
77:12276–12284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Morrison JA, Gulley ML, Pathmanathan R and
Raab-Traub N: Differential signaling pathways are activated in the
Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma
and Hodgkin lymphoma. Cancer Res. 64:5251–5260. 2004. View Article : Google Scholar
|
|
37.
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
38.
|
Yu JM, Jun ES, Jung JS, et al: Role of
Wnt5a in the proliferation of human glioblastoma cells. Cancer
Lett. 257:172–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Weeraratna AT, Jiang Y, Hostetter G, et
al: Wnt5a signaling directly affects cell motility and invasion of
metastatic melanoma. Cancer Cell. 1:279–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Yamamoto H, Oue N, Sato A, et al: Wnt5a
signaling is involved in the aggressiveness of prostate cancer and
expression of metalloproteinase. Oncogene. 29:2036–2046. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Torii K, Nishizawa K, Kawasaki A, et al:
Anti-apoptotic action of Wnt5a in dermal fibroblasts is mediated by
the PKA signaling pathways. Cell Signal. 20:1256–1266. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Mikels AJ and Nusse R: Purified Wnt5a
protein activates or inhibits beta-catenin-TCF signaling depending
on receptor context. PLoS Biol. 4:e1152006. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Fang W, Li X, Jiang Q, et al:
Transcriptional patterns, biomarkers and pathways characterizing
nasopharyngeal carcinoma of Southern China. J Transl Med. 6:322008.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Shi W, Bastianutto C, Li A, et al:
Multiple dysregulated pathways in nasopharyngeal carcinoma revealed
by gene expression profiling. Int J Cancer. 119:2467–2475. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Sriuranpong V, Mutirangura A, Gillespie
JW, et al: Global gene expression profile of nasopharyngeal
carcinoma by laser capture microdissection and complementary DNA
microarrays. Clin Cancer Res. 10:4944–4958. 2004. View Article : Google Scholar : PubMed/NCBI
|
